This medication is taken by intravenous (IV) infusion.
Ocrevus™ is a humanized monoclonal antibody that targets CD20 positive B lymphocytes ( a type of white blood cell), which contribute to nerve damage in MS.
Ocrevus is approved by the FDA for the treatment of patients with relapsing or primary progressive forms of MS.
Click to read the Prescribing Information for healthcare professionals.
Click to read the Medication Guide for patients.
Call Genentech at 1-844-OCREVUS (1-844-627-3887)
Financial Assistance ProgramGenentech Access Solutions
1-844-OCREVUS (1-844-627-3887) or 1-866-4ACCESS (866-422-2377)
National Infusion Center Association - non-profit patient advocacy organization which offers an online Infusion Center Finder to locate centers throughout the U.S. that administer IV/injectable medications. NICA also provides online consumer education to help patients learn more about infusion services.